IC
CLDX icon

Ikarian Capital’s Celldex Therapeutics CLDX Stock Holding History

Ikarian Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,800
Closed -$323K – 145
2025
Q1 		$323K Buy
+17,800
New +$398K 0.04% 127
2024
Q4 		– Sell
-305,500
Closed -$10.4M – 182
2024
Q3 		$10.4M Buy
+305,500
New +$11.6M 1.45% 17
2022
Q3 		– Sell
-506,500
Closed -$13.7M – 120
2022
Q2 		$13.7M Buy
506,500
+162,400
+47% +$4.72M 2.49% 8
2022
Q1 		$11.7M Sell
344,100
-249,700
-42% -$7.98M 1.54% 16
2021
Q4 		$22.9M Sell
593,800
-197,800
-25% -$8.62M 3.42% 6
2021
Q3 		$42.7M Buy
791,600
+191,600
+32% +$8.99M 3.01% 6
2021
Q2 		$20.1M Buy
600,000
+96,500
+19% +$2.65M 1.62% 10
2021
Q1 		$10.4M Buy
503,500
+103,500
+26% +$2.38M 0.35% 66
2020
Q4 		$7.01M Buy
400,000
+336,200
+527% +$6.05M 0.31% 76
2020
Q3 		$946K Sell
63,800
-210,700
-77% -$2.47M 0.07% 129
2020
Q2 		$3.57M Buy
+274,500
New +$1.22M 0.28% 80

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Ikarian Capital's CLDX Position: Q1 2026 in Review

Ikarian Capital opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 461,247 shares worth $14.6M. The stake represents 1.19% of the portfolio and ranks #21 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in CLDX as recently as Q1 2023.

Ikarian Capital first reported a position in CLDX in Q2 2020 and has held it in 13 quarters since. The position peaked at $23.9M in Q4 2020. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Ikarian Capital held 461,247 shares of Celldex Therapeutics worth $14.6M as of Q1 2026.
  • Celldex Therapeutics was a new Ikarian Capital position in Q1 2026.
  • Celldex Therapeutics made up 1.19% of Ikarian Capital's portfolio in Q1 2026, its #21 holding.
  • Ikarian Capital first reported a position in Celldex Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • Ikarian Capital's Celldex Therapeutics position peaked at $23.9M in Q4 2020.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.